A new Alzheimer's drug called donanemab could be available on the NHS by 2025, the i reports, hailing it as a "breakthrough".
Researchers have found that treatment appears to slow the pace of the disease by a third, but there are some potential side effects - including brain swelling, the paper notes.
Like Leqembi and Aduhelm, donanemab is a monoclonal antibody that attacks plaque in the brain, which is made up of a protein called amyloid.
Amyloid plaques lead to the spread of another protein called tau. Both amyloid and tau proteins lead to the development of Alzheimer’s disease.
This post was last modified on July 18, 2023 10:52 pm